Assessment and treatment of psoriatic spondylitis

Current Rheumatology Reports

Volumn 11, Issue 4, 2009, Pages 278-283

  Nash, Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANALGESIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETORICOXIB; GLUCOCORTICOID; GOLD SALT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; THALIDOMIDE;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; METABOLIC SYNDROME X; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; SCREENING TEST; TERATOGENICITY; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BACK PAIN; BIOLOGICAL FACTORS; HUMANS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS;

EID: 70449686219     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0039-8     Document Type: Review

References (46)

1. Resnick D, Niwayama G: Psoriatic arthritis. In Bone and Joint Imaging. Edited by Resnick D. Philadelphia: WB Saunders; 1989:320-328.
2. P.S. Helliwell P. Hickling V. Wright 1998 Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, and reactive arthritis? Ann Rheum Dis 57 135 140 9640127 10.1136/ard.57.3.135 1:STN:280:DyaK1czgsVejuw%3D%3D
3. D.D. Gladman B. Brubacher D. Buskila, et al. 1993 Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis Clin Invest Med 16 1 7 8467576 1:STN:280: DyaK3s3itlegsQ%3D%3D
4. C. Salvarani P. Macchioni T. Cremonesi, et al. 1992 The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study Ann Rheum Dis 51 73 77 1540041 10.1136/ard.51.1.73 1:STN:280: DyaK387ntFGluw%3D%3D
5. K. Laiho M. Kauppi 2002 The cervical spine in patients with psoriatic arthritis Ann Rheum Dis 61 650 652 12079912 10.1136/ard.61.7.650 1:STN:280:DC%2BD38zjslaiuw%3D%3D (Pubitemid 34717782)
6. P. Nash 2006 Therapies for axial disease in psoriatic arthritis. A systematic review J Rheumatol 33 1431 1434 16724371
7. D.D. Gladman R.D. Inman R.J. Cook, et al. 2007 International Spondyloarthritis Interobserver Reliability Exercise-The INSPIRE Study: I. Assessment of spinal measures J Rheumatol 34 1733 1739 17611985
8. V. Chandran F.D. O'shea C.T. Schentag, et al. 2007 Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis J Rheumatol 34 2463 2465 18050375
9. J.L. Fernandez-Sueiro A. Willisch S. Pertega-Diaz, et al. 2009 Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis Arthritis Rheum 61 386 392 19248134 10.1002/art.24280
10. L.H. Daltroy M.G. Larson N.W. Roberts M.H. Liang 1990 A modification of the Health Assessment Questionnaire for the spondyloarthropathies J Rheumatol 17 946 950 2213762 1:STN:280:DyaK3M%2Fht1CisQ%3D%3D
11. F. Wolfe K. Michaud T. Pincus 2004 Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire Arthritis Rheum 50 3296 3305 15476213 10.1002/art.20549 (Pubitemid 39372007)
12. Y.Y. Leung L.S. Tam E.W. Kun, et al. 2008 Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses J Rheumatol 35 1613 1621 18597399
13. C. Salvarani P. Macchioni T. Cremonesi, et al. 1992 The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study Ann Rheum Dis 51 73 77 1540041 10.1136/ard.51.1.73 1:STN:280: DyaK387ntFGluw%3D%3D
14. E. Lubrano A. Marchesoni I. Olivieri, et al. 2009 Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis J Rheumatol 36 1006 1011 19332625 10.3899/jrheum.080491
15. L. Williamson J.L. Dockerty N. Dalbeth, et al. 2004 Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by MRI in psoriatic arthritis Rheumatology (Oxford) 43 85 88 10.1093/rheumatology/ keg475 1:STN:280:DC%2BD3sngtVSktg%3D%3D (Pubitemid 38088373)
16. B. Muche M. Bollow R.J. Francois, et al. 2003 Anatomic structures involved in early- and late-stage sacroiliitis in spondyloarthritis. A detailed analysis by contrast-enhanced magnetic resonance imaging Arthritis Rheum 48 1374 1384 12746910 10.1002/art.10934 1:STN:280:DC%2BD3s3itlKgtA%3D%3D (Pubitemid 36554536)
17. J. Braun X. Baraliakos W. Golder, et al. 2003 Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system Arthritis Rheum 48 1126 1136 12687557 10.1002/art.10883 1:STN:280: DC%2BD3s7mvVCmtg%3D%3D (Pubitemid 36418256)
18. F. McQueen M. Lassere M. Østergaard 2006 Magnetic resonance imaging in psoriatic arthritis: a review of the literature Arthritis Res Ther 8 207 214 16569257 10.1186/ar1934
19. N.J. McHugh C. Balachrishnan S.M. Jones 2003 Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study Rheumatology 42 778 783 12730539 10.1093/rheumatology/keg217 1:STN:280:DC%2BD3s3kvVGltA%3D%3D (Pubitemid 37220911)
20. D.D. Gladman C.T. Schentag B.D. Tom, et al. 2009 Psoriatic Arthritis Screen (ToPAS) questionnaire for psoriatic arthritis: the Toronto Development and initial validation of a screening Ann Rheum Dis 68 497 501 18445625 10.1136/ard.2008.089441 1:STN:280:DC%2BD1M3gsFymtw%3D%3D
21. Dagfinrud H, Kvien TK, Hagen KB: Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2004, CD002822. doi:10.1002/14651858. CD002822.pub2.
22. A. Hidding S. van der Linden X. Gielen, et al. 1994 Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial Arthritis Care Res 7 90 96 7857999 10.1002/art.1790070208 1:STN:280:DyaK2M7mtFClug%3D%3D (Pubitemid 24181338)
23. A. Wanders D. Heijde R. Landewé, et al. 2005 Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial Arthritis Rheum 52 1756 1765 15934081 10.1002/art.21054 1:CAS:528:DC%2BD2MXlvFChurw%3D (Pubitemid 40852884)
24. D. van der Heijde H.S. Baraf C. Ramos-Remus, et al. 2005 Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study Arthritis Rheum 52 1205 1215 15818702 10.1002/art.20985 (Pubitemid 40530128)
25. N.D. Peters L. Ejstrup 1992 Intravenous methylprednisolone pulse therapy in ankylosing spondylitis Scand J Rheumatol 21 134 138 1604251 10.3109/03009749209095085 1:STN:280:DyaK383psVOqtw%3D%3D
26. G. Mintz R.D. Enríquez U. Mercado, et al. 1981 Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis Arthritis Rheum 24 734 736 7236329 10.1002/art.1780240521 1:STN:280:DyaL3M3gslersA%3D%3D (Pubitemid 11099293)
27. D.O. Clegg D.J. Reda M.H. Weisman, et al. 1996 Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veteran Affairs Cooperative Study Arthritis Rheum 39 2004 2012 8961905 10.1002/art.1780391209 1:CAS:528:DyaK2sXjt12lsQ%3D%3D (Pubitemid 27009068)
28. B.J. Dekker-Saeys B.A. Dijkmans G.N. Tytgat 2000 Treatment of spondyloarthropathy with 5 aminosalicylic acid (mesalazine): an open trial J Rheumatol 27 723 726 10743816 1:CAS:528:DC%2BD3cXit1Smt7w%3D
29. L. Gonzalez-Lopez A. Garcia-Gonzalez M. Vazquez-Del-Mercado, et al. 2004 Efficacy of methotrexate in ankylosing spondylitis. A randomized, double blind, placebo controlled trial J Rheumatol 31 1568 1574 15290737 1:CAS:528: DC%2BD2cXnt1elsr8%3D
30. K. Grasedyck M. Schattenkirchner K. Bandilla 1990 The treatment of ankylosing spondylitis with auranofin (Ridaura) Z Rheumatol 49 98 99 2190436 1:STN:280:DyaK3c3ntlOruw%3D%3D
31. J. Palit J. Hill H.A. Capell, et al. 1990 A multicentre double blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis Br J Rheumatol 29 280 283 2116206 10.1093/rheumatology/ 29.4.280 1:STN:280:DyaK3czjsFGkug%3D%3D
32. G. Jones M. Crotty P. Brooks 1997 Psoriatic arthritis: a quantitative overview of therapeutic options. Psoriatic Arthritis Meta-Analysis Study Group Br J Rheumatol 36 95 99 9117186 10.1093/rheumatology/36.1.95 1:STN:280:DyaK2s3ivVertA%3D%3D
33. J.C. Wei T.W. Chan H.S. Lin, et al. 2003 Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial J Rheumatol 30 2627 2631 14719205 1:CAS:528:DC%2BD2cXktVCguro%3D
34. J.P. Kaltwasser P. Nash D. Gladman, et al. 2004 Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial Arthritis Rheum 50 1939 1950 15188371 10.1002/art.20253 1:CAS:528: DC%2BD2cXlsFaqtbo%3D (Pubitemid 38725106)
35. J.C. van Denderen M. van der Paardt M.T. Nurmohamed, et al. 2005 Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis Ann Rheum Dis 64 1761 1764 15901634 10.1136/ard.2005.036491 (Pubitemid 41667152)
36. I. Olivieri C. Salvarani F. Cantini, et al. 1997 Therapy with cyclosporine in psoriatic arthritis Semin Arthritis Rheum 27 36 43 9287388 10.1016/S0049-0172(97)80035-2 1:CAS:528:DyaK2sXmt1Wjtr0%3D (Pubitemid 27374247)
37. A.D. Fraser A.W. van Kuijk R. Westhovens, et al. 2005 A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis Ann Rheum Dis 64 859 864 15528283 10.1136/ard.2004.024463 1:CAS:528: DC%2BD2MXls1als7k%3D (Pubitemid 40733909)
38. W.P. Maksymowych G.S. Jhangri A.A. Fitzgerald, et al. 2002 A six-month randomized, controlled, double-blind, doseresponse comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis Arthritis Rheum 46 766 773 11920413 10.1002/art.10139 1:CAS:528:DC%2BD38XisFOmtLw%3D (Pubitemid 34214258)
39. A.L. Tan H. Marzo-Ortega P. O'Connor, et al. 2004 Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study Ann Rheum Dis 63 1041 1045 15066864 10.1136/ard.2004.020800 1:CAS:528: DC%2BD2cXnvFWktr8%3D (Pubitemid 39120352)
40. P.J. Mease D.D. Gladman E.C. Keystone 2006 Alefacept in combination with methotrexate for the treatment of psoriatic arthritis results of a randomized, doubleblind, placebo-controlled study Arthritis Rheum 54 1638 1645 16646026 10.1002/art.21870 1:CAS:528:DC%2BD28XlsFWjsrY%3D
41. P.J. Mease B.S. Goffe J. Metz, et al. 2000 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 385 390 10972371 10.1016/S0140-6736(00)02530-7 1:CAS:528:DC%2BD3cXls1Cksr8%3D
42. P.J. Mease A.J. Kivitz F.X. Burch, et al. 2004 Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 2264 2272 15248226 10.1002/art.20335 1:CAS:528: DC%2BD2cXmsVansbc%3D (Pubitemid 38924405)
43. C.E. Antoni A. Kavanaugh B. Kirkham, et al. 2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) Arthritis Rheum 52 1227 1236 15818699 10.1002/art.20967 1:CAS:528:DC%2BD2MXktFCktbw%3D (Pubitemid 40530131)
44. P.J. Mease D.D. Gladman C.T. Ritchlin, et al. 2005 Adalimumab for the treatment of psoriasis with moderately to severely active psoriatic arthritis Arthritis Rheum 52 3279 3289 16200601 10.1002/art.21306 1:CAS:528: DC%2BD2MXhtF2msrjP (Pubitemid 41447111)
45. A. Kavanaugh I. McInnes P. Mease, et al. 2009 Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis twenty-four-week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum 60 976 986 19333944 10.1002/art.24403 1:CAS:528:DC%2BD1MXltFenu7g%3D
46. F. Conti F. Ceccarelli E. Marocchi, et al. 2007 Switching tumour necrosis factor-a antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period Ann Rheum Dis 66 1393 1397 17613555 10.1136/ard.2007.073569 1:CAS:528:DC%2BD2sXht1Wnu73M (Pubitemid 47492489)